Pegylated IFN-&alpha; 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 15

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

279

HTML

1785

Figures (1-3)

311

Tables (1-2)

197

Sum=2572

Apr 21, 2006 (publication date) through Dec 11, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Apr 21, 2006; 12(15): 2417-2422
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2417

Full Size Figure Download Figure

Figure 1 Median HBV DNA titers during PEG-IFN-α 2b therapy and during follow-up.

Citation: Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2417-2422
URL: https://www.wjgnet.com/1007-9327/full/v12/i15/2417.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i15.2417